XNYS
STVN
Market cap5.31bUSD
Oct 08, Last price
19.21USD
1D
-1.18%
1Q
-1.94%
IPO
-1.69%
Name
Stevanato Group SpA
Chart & performance
P/E
34.83
P/S
4.10
EPS
0.49
Div yield, %
0.32%
Shrs. gr., 5y
0.62%
Rev. gr., 5y
11.47%
Revenues
1.14b
+3.21%
Net income
134m
+14.01%
CFO
275m
+76.40%
Dividend
Jun 11, 20260.0622 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
Related entities
Parent
STEVANATO HOLDING S.R.L.
Subsidiaries (3)
NUOVA OMPI S.R.L.
OMPI N.A. S DE RL DE CV
S.P.A.M.I. S.R.L.
Key people
Sergio Stevanato
Emeritus Chairman
Franco Stevanato
Executive Chairman of the Board, Chief Executive Officer · since 2024
Marco Lago
Chief Financial Officer · since 2020
Riccardo Butta
President, Americas · since 2022
Ugo Gay
Chief Operations Officer · since 2024
Carla Costa
Chief Human Resources Officer · since 2025
Michele Monico
President - DDS and IVD Business Unit · since 2025
Raffaele Pace
President - Engineering Business Unit · since 2025
Mauro Stocchi
Chief Business Officer
Franco Moro
Director · since 2024
Alvise Spinazzi
Director · since 2011
Independent Director · since 2018
Fabrizio Bonanni
Independent Director · since 2013
Fabio Buttignon
Independent Director · since 2014
Independent Director · since 2021
Karen Flynn
Independent Director · since 2024
Independent Director · since 2018
Luciano Santel
Independent Director · since 2024
Headquarters & legal address
VIA MOLINELLA, 17
PIOMBINO DESE, PD 35017
IT
PIOMBINO DESE, PD 35017
IT
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||